%0 Journal Article
%T Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients - Real World Study.
%A Balcázar-Valencia CM
%A García-Ramos AF
%A Osorio-Toro LM
%A Ordoñez-Guzmán YA
%A Buitrago-Gómez N
%A Cabarcas-López WF
%A Vizcaino-Guerrero CJ
%A Daza-Arana JE
%A Ramírez-Rincón A
%A Restrepo-Erazo K
%J Diabetes Metab Syndr Obes
%V 17
%N 0
%D 2024
%M 38616987
%F 3.249
%R 10.2147/DMSO.S443115
%X <B>UNASSIGNED: </B>Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia.<BR><B>UNASSIGNED: </B>The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up.<BR><B>UNASSIGNED: </B>Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD -2.74 CI -1.95 to -3.52 in 6 months), fasting plasma glucose levels, body weight (MD -7.11 CI -5.97 to -8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events.<BR><B>UNASSIGNED: </B>This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.